Cabometyx Shows Strong Efficacy, Reducing Progression/Death Risk by Up to 74% in Neuroendocrine Tumors
Summary
Exelixis announced highly positive clinical trial results for its drug Cabometyx, demonstrating a 74% reduction in the risk of progression or death in non-functional neuroendocrine tumors (NET) and a 60% reduction in functional NET. These strong efficacy rates are significant for a key product in Exelixis's portfolio. This new data could expand Cabometyx's market potential and strengthen its competitive position in the treatment of neuroendocrine tumors, potentially driving future revenue growth.
At the time of this announcement, EXEL was trading at $50.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $33.76 to $52.96. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.